Generic and biosimilar drugmaker Sandoz has agreed to pay $265 million to settle allegations of price-fixing in a Pennsylvania lawsuit.

Sandoz makes its first acquisition since spinning out of Novartis, buying a Lucentis biosimilar from Coherus that will boost its position in the US market.

The active ingredients in this low-abrasive toothpaste are sodium fluoride and tri-calcium phosphate. It works to remineralize lesions that exist throughout teeth, as well as those on surface enamel.